Publications by authors named "Felix Carl Saalfeld"

Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven non-small cell lung cancer (EGFR+ NSCLC). Little is known about the optimal management of SCT patients. This study aimed to compare outcomes under platinum/etoposide chemotherapy alone (chemo) or in combination with EGFR inhibitors (EGFRi+chemo) or immune checkpoint inhibitors (ICI+chemo).

View Article and Find Full Text PDF
Article Synopsis
  • * A study of 218 OMD NSCLC patients showed that those with fewer metastases and female patients had significantly longer overall survival rates, with a median OS of 27.8 months and a 5-year survival rate of 29%.
  • * Patients who underwent comprehensive local ablation combined with systemic therapy experienced improved recurrence-free survival, highlighting that adding immunotherapy could enhance outcomes, indicating a potential for a curative approach.
View Article and Find Full Text PDF

EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program.

View Article and Find Full Text PDF

In no other cancer is clinical practice as close to the ideals of personalized oncology as in the treatment of non-small cell lung cancer (NSCLC). Here, we briefly outline the basic principles of molecular analysis. The focus of the article is on the clinical utility of targeted therapy.

View Article and Find Full Text PDF